Ligand Pharmaceuticals Incorporated (LGND) has a consensus analyst rating of Buy, based on 17 analysts covering the stock. Of those, 12 recommend buying, 4 recommend holding, and 1 recommend selling.
The analyst consensus price target for LGND is $248.00, representing a +6.7% upside from the current price of $232.34. Price targets range from a low of $230.00 to a high of $275.00.
